Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2007, Article ID 15929, 5 pages
http://dx.doi.org/10.1155/2007/15929
Clinical Study

The Serum High-Sensitive C Reactive Protein and Homocysteine Levels to Evaluate the Prognosis of Acute Ischemic Stroke

1Department of Neurology, Medical Faculty, Firat University, Elazig 23119, Turkey
2Department of Immunology, Medical Faculty, Firat University, Elazig 23119, Turkey
3Department of Cardiology, Erzurum Informary Hospital, Erzurum 25100, Turkey

Received 14 December 2006; Accepted 8 February 2007

Copyright © 2007 Tahir Yoldas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Zivin, “Factors determining the therapeutic window for stroke,” Neurology, vol. 50, no. 3, pp. 599–603, 1998. View at Google Scholar
  2. W.-D. Heiss, A. Thiel, M. Grond, and R. Graf, “Which targets are relevant for therapy of acute ischemic stroke?” Stroke, vol. 30, no. 7, pp. 1486–1489, 1999. View at Google Scholar
  3. A. Furlan, R. Higashida, L. Wechsler et al., “Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism,” Journal of the American Medical Association, vol. 282, no. 21, pp. 2003–2011, 1999. View at Publisher · View at Google Scholar
  4. S. M. Wolpert, H. Bruckmann, R. Greenlee, L. Wechsler, M. S. Pessin, and G. J. Del Zoppo, “Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA acute stroke study group,” American Journal of Neuroradiology, vol. 14, no. 1, pp. 3–13, 1993. View at Google Scholar
  5. T. J. DeGraba, “The role of inflammation after acute stroke: utility of pursuing anti-adhesion molecule therapy,” Neurology, vol. 51, no. 3, supplement, pp. S62–S68, 1998. View at Google Scholar
  6. I. S. Ockene, C. E. Matthews, N. Rifai, P. M. Ridker, G. Reed, and E. Stanek, “Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults,” Clinical Chemistry, vol. 47, no. 3, pp. 444–450, 2001. View at Google Scholar
  7. P. M. Ridker, “High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease,” Circulation, vol. 103, no. 13, pp. 1813–1818, 2001. View at Google Scholar
  8. N. Rifai and P. M. Ridker, “High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease,” Clinical Chemistry, vol. 47, no. 3, pp. 403–411, 2001. View at Google Scholar
  9. N. S. Rost, P. A. Wolf, C. S. Kase et al., “Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study,” Stroke, vol. 32, no. 11, pp. 2575–2579, 2001. View at Google Scholar
  10. G. J. Blake and P. M. Ridker, “Inflammatory bio-markers and cardiovascular risk prediction,” Journal of Internal Medicine, vol. 252, no. 4, pp. 283–294, 2002. View at Publisher · View at Google Scholar
  11. R. Ross, “Atherosclerosis—an inflammatory disease,” New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar
  12. V. Pasceri, J. T. Willerson, and E. T. H. Yeh, “Direct proinflammatory effect of C-reactive protein on human endothelial cells,” Circulation, vol. 102, no. 18, pp. 2165–2168, 2000. View at Google Scholar
  13. L. H. Kuller, R. P. Tracy, J. Shaten, and E. N. Meilahn, “Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial,” American Journal of Epidemiology, vol. 144, no. 6, pp. 537–547, 1996. View at Google Scholar
  14. R. S. Rosenson and W. Koenig, “High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease,” Current Opinion in Cardiology, vol. 17, no. 4, pp. 325–331, 2002. View at Publisher · View at Google Scholar
  15. P. M. Ridker, M. Cushman, M. J. Stampfer, R. P. Tracy, and C. H. Hennekens, “Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease,” Circulation, vol. 97, no. 5, pp. 425–428, 1998. View at Google Scholar
  16. P. M. Ridker, S. S. Bassuk, and P. P. Toth, “C-reactive protein and risk of cardiovascular disease: evidence and clinical application,” Current Atherosclerosis Reports, vol. 5, no. 5, pp. 341–349, 2003. View at Google Scholar
  17. G. Boysen, T. Brander, H. Christensen, R. Gideon, and T. Truelsen, “Homocysteine and risk of recurrent stroke,” Stroke, vol. 34, no. 5, pp. 1258–1261, 2003. View at Publisher · View at Google Scholar
  18. J. Selhub, P. F. Jacques, A. G. Bostom et al., “Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis,” New England Journal of Medicine, vol. 332, no. 5, pp. 286–291, 1995. View at Publisher · View at Google Scholar
  19. J. W. Eikelboom, G. J. Hankey, S. S. Anand, E. Lofthouse, N. Staples, and R. I. Baker, “Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke,” Stroke, vol. 31, no. 5, pp. 1069–1075, 2000. View at Google Scholar
  20. P. J. Kelly, J. Rosand, J. Kistler et al., “Homocysteine, MTHFR 677C?T polymorphism, and risk of ischemic stroke: results of a meta-analysis,” Neurology, vol. 59, pp. 529–536, 2002. View at Google Scholar
  21. C. J. Smith, H. C. Emsley, C. M. Gavin et al., “Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome,” BMC Neurology, vol. 4, no. 1, p. 2, 2004. View at Publisher · View at Google Scholar
  22. N. B. Beamer, B. M. Coull, W. M. Clark, J. S. Hazel, and J. R. Silberger, “Interleukin-6 and interleukin-1 receptor antagonist in acute stroke,” Annals of Neurology, vol. 37, no. 6, pp. 800–805, 1995. View at Publisher · View at Google Scholar
  23. N. J. Rothwell and J. K. Relton, “Involvement of cytokines in acute neurodegeneration in the CNS,” Neuroscience and Biobehavioral Reviews, vol. 17, no. 2, pp. 217–227, 1993. View at Publisher · View at Google Scholar
  24. M. Chopp, R. L. Zhang, H. Chen, Y. Li, N. Jiang, and J. R. Rusche, “Postischemic administration of an anti-Mac-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in rats,” Stroke, vol. 25, no. 4, pp. 869–875, 1994. View at Google Scholar
  25. N. Jiang, M. Moyle, H. R. Soule, W. E. Rote, and M. Chopp, “Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats,” Annals of Neurology, vol. 38, no. 6, pp. 935–942, 1995. View at Publisher · View at Google Scholar
  26. K. W. Muir, C. J. Weir, W. Alwan, I. B. Squire, and K. R. Lees, “C-reactive protein and outcome after ischemic stroke,” Stroke, vol. 30, no. 5, pp. 981–985, 1999. View at Google Scholar
  27. M. Di Napoli, F. Papa, and V. Bocola, “C-reactive protein in ischemic stroke: an independent prognostic factor,” Stroke, vol. 32, no. 4, pp. 917–924, 2001. View at Google Scholar
  28. J. C. Chambers, A. McGregor, J. Jean-Marie, O. A. Obeid, and J. S. Kooner, “Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy,” Circulation, vol. 99, no. 9, pp. 1156–1160, 1999. View at Google Scholar
  29. F. Nappo, N. De Rosa, R. Marfella et al., “Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins,” Journal of the American Medical Association, vol. 281, no. 22, pp. 2113–2118, 1999. View at Publisher · View at Google Scholar
  30. J.-H. Yoo, C.-S. Chung, and S.-S. Kang, “Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis,” Stroke, vol. 29, no. 12, pp. 2478–2483, 1998. View at Google Scholar
  31. D. J. Meiklejohn, M. A. Vickers, R. Dijkhuisen, and M. Greaves, “Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke,” Stroke, vol. 32, no. 1, pp. 57–62, 2001. View at Google Scholar
  32. A. Lindgren, L. Brattstrom, B. Norrving, B. Hultberg, A. Andersson, and B. B. Johansson, “Plasma homocysteine in the acute and convalescent phases after stroke,” Stroke, vol. 26, no. 5, pp. 795–800, 1995. View at Google Scholar
  33. M. Ribó, J. Montaner, J. Monasterio et al., “Role of homocysteine in the acute phase of stroke,” Neurologia, vol. 19, no. 1, pp. 10–14, 2004. View at Google Scholar
  34. J. Pniewski, M. Chodakowska-Zebrowska, R. Woźniak, K. Stępień, and A. Stafiej, “Plasma homocysteine level and the course of ischemic stroke,” Acta Neurobiologiae Experimentalis, vol. 63, no. 2, pp. 127–130, 2003. View at Google Scholar